ManishAShahMD

PubMed

• Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer.
  Wasat Mansoor, Seongjung Joo, Josephine M Norquist, Ken Kato, Jong-Mu Sun
  The Oncologist. 2024-10-03
• 1 citations
  Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
  Kohei Shitara, Rui-Hua Xu, Jaffer A Ajani, Diarmuid Moran, Abraham Guerrero
  Gastric Cancer. 2024-09-01
• 1 citations
  Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction: A Network Meta-Analysis.
  Ulrich Ronellenfitsch, Juliane Friedrichs, Emilie Barbier, Gary A Bass, Bryan Burmeister
  JAMA Network Open. 2024-08-01

Journal Articles

• Template for Reporting Results of HER2 (ERBB2) Biomarker Testing of Specimens From Patients With Adenocarcinoma of the Stomach or Esophagogastric Junction  
  Bartley AN, Christ J, Fitzgibbons PL, et al, Archives of pathology & laboratory medicine, 10/2/2014
• The role of (1)(8)F-FDG PET imaging in upper gastrointestinal malignancies  
  Dai T, Popa E, Shah MA, Current treatment options in oncology, 9/1/2014
• Is gastric cancer different in Korea and the United States? Impact of tumor location on prognosis  
  Shim JH, Song KY, Jeon HM, Park CH, Jacks LM, Gonen M, Shah MA, Brennan MF, Coit DG, Strong VE, Ann Surg Oncol, 7/1/2014
• Gastric cancer drug trials - are women second class citizens?  
  Shah MA, Nature reviews. Clinical oncology, 7/1/2014
• Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach  
  Ocean AJ, Christos P, Sparano JA, et al, Investigational new drugs, 6/1/2014
• Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma  
  Bomboat ZM, Tang LH, Vinuela E, Kuk D, Gonen M, Shah MA, Brennan MF, Coit DG, Strong VE, Ann Surg Oncol, 1/7/2014
• Isolation of breast and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device  
  Galletti G, Sung MS, Vahdat LT, Shah MA, Santana SM, Altavilla G, Kirby BJ, Giannakakou P, Lab Chip, 1/1/2014
• Gastrointestinal cancer: targeted therapies in gastric cancer-the dawn of a new era  
  Shah MA, Nature reviews. Clinical oncology, 1/1/2014
• Gastrointestinal cancer: Targeted therapies in gastric cancer - the dawn of a new era  
  Shah MA, Nat Rev Clin Oncol, 1/1/2014
• An individual coding polymorphism and the haplotype of the SPARC gene predict gastric cancer recurrence  
  Winder T, Wilson P M , Yang D, Zhang W, Ning Y, Power D G , Bohanes P, Gerger A , Tang L H , Shah M, Lenz HJ, Pharmacogenomics J, 8/1/2013
• Conditional probability of survival nomogram for 1-, 2-, and 3-year survivors after an r0 resection for gastric cancer  
  Dikken JL, Baser RE, Gonen M, Kattan MW, Shah MA, Verheij M, van de Velde CJ, Brennan MF, Coit DG, Annals of Surgical Oncology, 5/1/2013
• Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States  
  Wakatsuki T, LaBonte MJ, Bohanes PO, Zhang W, Yang D, Azuma M, Barzi A, Ning Y, Loupakis F, Saadat S, Volz N, Stintzing S, El-Khoueiry R, Koizumi W, Watanabe M, Shah M..., Mol Cancer Ther, 1/1/2013
• Unanswered questions in the management of gastroesophageal junction adenocarcinoma  
  Shah MA, American Society of Clinical Oncology, 1/1/2013
• Capecitabine in the treatment of esophageal and gastric cancers  
  Popa EC and Shah MA, Expert Opin Invest Drugs, 1/1/2013
• hase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Cisplatin and Irinotecan-refractory Metastatic Esophagogastric Cancer  
  Janjigian YY, Ku GY, Campbell JC, Shah MA, Capanu M, Kelsen DP, Ilson DH, American Journal of Clinical Oncol, 12/1/2012
• Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Cisplatin and Irinotecan-refractory Metastatic Esophagogastric Cancer  
  Janjigian YY, Ku GY, Campbell JC, Shah MA, Capanu M, Kelsen DP, Ilson DH, American Journal of Clinical Oncology, 12/1/2012
• Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and US International Collaborative Analysis  
  Janjigian YY, Werner D, Pauligk C, Steinmetz S, Kelsen DP, Jager E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE, Annals of Oncology, 6/11/2012
• Bevacizumab in combination with chemotherapy as first line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial  
  Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Xu JM, Yong WP, Langer B, Delmar P, Scherer SJ, Shah MA, Journal of Clinical Oncology, 5/7/2012
• A prospective evaluation of the utility of FDG-PET/CT in staging locally advanced gastric cancer  
  Smyth EC, Schoder H, Strong VE, Capanu M, Kelsen DK, Coit DG, Shah MA, Cancer, 5/1/2012
• Tobacco use is associated with increased recurrence and death from gastric cancer  
  Smyth EC, Capanu M, Janjigian YY, Kelsen DK, Coit D, Strong VE, Shah MA, Annals of Surgical Oncology, 3/7/2012
• A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR < 30 ml/min) and end stage renal disease on hemodialysis  
  Jhaveri KD, Flombaum C, Shah M, Latcha S, J Oncol Pharm Pract, 3/1/2012
• Treatment of resectable gastric cancer  
  Dikken JL, van de Velde CJ, Coit DG, Shah MA, Verhij M, Cats A, Therap Adv Gastroenterol, 1/1/2012
• Management of advanced gastric cancer  
  Price TJ, Shapiro JD, Segelov E, Karapetis CS, Pavlakis N, Van Cutsem E, Shah MA, Kang YK, Tebbutt NC, Expert Rev Gastroenterol Hepatol, 1/1/2012
• A 71-year-old man with a large cystic pancreatic mass  
  Mukherji D, Faraj W, Khalife M, Shamseddine A, El Majzoub N, Zaatari G, Shah M, Abou-Alfa GK, O'Reilly EM, Gastrointestinal Cancer Res, 1/1/2012
• Role of (F) 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies  
  Smyth EC and Shah MA, World Journal of Gastroenterology, 12/1/2011
• Join now to see all

Books/Book Chapters

• Textbook of Uncommon Cancer. 
  Chapter: Uncommon Cancers of the Stomach. 
  Popa E, Schnoll-Sussman F, Jesudian A, Nandakumar G, and Shah MAEditors: Raghavan, Blanke.Wiley-BlackwellEdition 4th,2012
• 100 Questions about Gastric Cancer. 
  Shah MA, Pinheiro NP, Shah BM (Eds)Editors: Shah MA, Pinheiro NP, Shah BM (Eds).Jones and Bartlett, Sudbury, MA2008
• Molecular Basis of Cancer. 
  Chapter: The Molecular Basis of Gastric and Gastroesophageal Adenocarcinoma. 
  Page 511 - 520Shah MA and Kelsen DPEditors: Mendelsohn, Howley, Thompson, Grey, and Israel.Saunders Elsevier, Philadelphia, PA2008
• Principals and Practice of Gastrointestinal Oncology. 
  Chapter: Gastrointestinal Oncology: Medical Oncology. 
  Page 81 - 87Asmis TR and Shah MAEditors: Kelsen, Daly, Kern, Levin, Tepper, and Van Custem.Lippincott Williams &Wilkins, Philadelphia, PA2008
• DX/RX Oncology 
  Shah MA (Eds)Editors: Shah MA (Eds).Jones and Bartlett, Sudbury, MA2006
• DX/RX: Upper Gastrointestinal Malignancies - Cancers of the Esophagus and Stomach. 
  Page 1 - 172Shah MA (Eds)Editors: Shah MA (Eds).Jones and Bartlett, Sudbury, MA2006
• Cell Cycle Modulation: An Emerging Target for Cancer Therapy. 
  Shah MA and Schwartz GK2003
• Research for Electrical Energy Systems - An Annual Report. 
  Chapter: Gaseous Dielectric Research. 
  Van Brunt R, Olthoff J, Stricklett K, Herron J, Shah MA, Wan H, Moore JWilliam E. Anderson1992
• Join now to see all

Abstracts/Posters

• Cancers of the Esophagus and Stomach.
  Shah MA, Gastrointestinal Cancers Symposium, San Francisco, CA, 1/16/2014
• Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients with advanced gastric ca...
  Shah MA, Gastrointestinal Cancers Symposium, San Francisco, CA, 1/19/2012
• Phase II study of preoperative chemotherapy with irinotecan and cisplatin for gastric cancer (NCI 5917): FDG PET/CT predicts patient outcome.
  Shah MA, ASCO, 6/3/2007

Lectures

• Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study. 
  2019 ASCO Annual Meeting - 6/1/2019
• Pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase 2 KEYNOTE-180 study. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
• Targeted therapies in gastric cancer. 
  Madrid, Spain - 6/26/2014
• Research Focus-Targeted Therapy for Second-line Treatment of Metastatic Gastric Cancer. 
  New York, NY - 2/27/2014
• Journal review 101- Evaluating Scholarly Articles. 
  San Francisco, CA - 1/16/2014
• Active New Agents in Esophagogastric Cancer. 
  11/6/2013
• Evolving Roles of Chemotherapy and Radiation for Gastric Cancer. 
  Atlanta, GA - 11/2/2013
• New Paradigm in Gastric Cancer. 
  10/31/2013
• Moving Towards Personalized Care for the Management of Advanced Gastric Cancer. 
  Cleveland, OH - 6/14/2013
• Targeted Therapy for Second-line Treatment of Metastatic Gastric Cancer. 
  New York, NY - 5/1/2013
• Subtypes in Gastric Cancer- Prognosis and Therapeutic Implications. 
  Madrid, Spain - 4/19/2013
• Utilizing Biomarkers and Technology in the Treatment Decision Process. 
  Rome, Italy - 2/17/2013
• Targeted therapies in upper gastrointestinal malignancies. 
  Seoul, Korea - 11/6/2012
• eOncoreview: The future of targeted therapy for upper GI malignancies. 
  Geneva, Switzerland - 8/7/2012
• Are all gastric cancers identical? 
  Barcelona, Spain - 6/28/2012
• Targeted agents in gastric cancer. 
  Barcelona, Spain - 6/28/2012
• New treatment strategies - Oncology Round Table. 
  6/8/2012
• Drug development in gastric cancer. 
  Bourdeaux, France - 2/18/2012
• Clinical significance of gastric cancer subtype on triple-drug therapy for gastric cancer. 
  Osaka, Japan - 2/10/2012
• Anti-Angiogenic Therapy for the Treatment of Gastric/Esophageal Cancer. 
  San Diego, CA - 2/4/2012
• The Future of Targeted Therapy in Upper Gastrointestinal Cancers. 
  San Francisco, CA - 1/19/2012
• The Development of Anti-Angiogenic Therapy in Gastric Cancer. 
  Boston, MA - 10/29/2011
• Adjuvant therapy in locally advanced gastric cancer: pre-, post-, or both. 
  San Francisco, CA - 10/27/2011
• Update on Gastric Cancer Emerging Treatment Modalities: Chemotherapy and Targeted Therapies. 
  New York, NY - 10/13/2011
• Gastrointestinal Oncology: Entering a New Era of Individualized Care. 
  New York, NY - 10/4/2011
• Join now to see all

Other

• Cancer of the stomach. 
  Shah M, Strong V
  1/1/2009
• The function of neuron specific kinesin heavy chain as assessed by antisense technology. 
  Manish A. Shah, Publ Harvard Medical School, Thesis
  2/1/1996